Human B cells producing cat allergen–specific IgG antibodies

Human B cells producing cat allergen–specific IgG antibodies represent a specific functional subset of the B cell repertoire involved in the immune response to Felis domesticus allergens, primarily Fel d 1. In the context of allergic disease, these cells are of significant interest because the production of allergen-specific IgG, particularly the IgG4 subclass, is associated with the development of peripheral immune tolerance. These antibodies act as 'blocking antibodies' that compete with IgE for allergen binding, thereby preventing the cross-linking of IgE on mast cells and basophils and subsequent degranulation. While not a therapeutic target in the traditional sense of a molecule to be inhibited, these B cells are the desired 'effectors' of successful allergen immunotherapy (AIT). Research into these cells focuses on understanding the B cell receptor (BCR) repertoire and the signaling pathways that drive the class-switch recombination from IgE to IgG4. Therapeutic strategies such as AIT or the administration of recombinant monoclonal IgG antibodies (passive immunization) leverage the protective role of these cells and their products to mitigate allergic symptoms and induce long-term clinical desensitization.

Other names

Fel d 1-specific IgG-producing B cellsCat allergen-specific B cellsIgG+ B cells specific for Fel d 1

Not applicable as this is a cell population rather than a molecular target. However, allergen immunotherapy (AIT) aims to induce the expansion of these cells to produce neutralizing IgG4 antibodies.